跳到正文
原文
Endpoints News 生物医药· Reynald Castaneda·· 27 天前AI 评分35

ESMO26大会:阿斯利康关注Keytruda的Padcev适应症;礼来的ADC药物挑战Elahere;Nubeqa瞄准早期前列腺癌

#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer

AI 导读

ESMO26大会预计吸引近4万名代表参会。阿斯利康探讨Keytruda在Padcev适应症领域的潜在布局。礼来ADC药物与Elahere展开竞争,Nubeqa聚焦早期前列腺癌治疗方案。

正文

MADRID — It’s been es­ti­mat­ed that al­most 40,000 del­e­gates will be at­tend­ing this year’s ES­MO con­gress over five days in Madrid. And on Sat­ur­day, they have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news